Bodily autonomy is not a privilege of geography.

The 2022 Supreme Court ruling in Dobbs v. Jackson Women's Health overturned Roe v. Wade and Planned Parenthood v. Casey, returning abortion regulation to the states. The result is a fragmented two-tier system. Roughly 14 states have enacted near-total bans (with narrow exceptions for life-threatening conditions or rape that often function poorly in practice). Another set has imposed substantial restrictions (gestational limits well before viability, mandatory waiting periods, parental notification, restrictions on medication abortion). The remaining states have either codified prior Roe-era access in state law or had it codified by ballot measure. Travel-for-care has expanded substantially: clinics in border states (Illinois, New Mexico, Kansas in some periods, Colorado) have absorbed flows from restrictive neighbors. The federal action options span scales. The Women's Health Protection Act would codify abortion access through fetal viability in federal statute; it has passed the House and stalled in the Senate. Federal action on medication abortion (mifepristone), interstate travel protection, and federally regulated facilities (military bases, VA) are smaller-scale levers that don't require the same political conditions.

Through 2022, contraception access in the United States was widely understood as a settled matter — covered without cost-sharing by most insurance under the ACA, broadly available, supported by overwhelming public majorities. Post-Dobbs, contraception has become a political fight in ways many observers did not anticipate. State-level efforts to redefine certain contraceptives (IUDs, emergency contraception, hormonal contraception in some framings) as abortifacients have advanced in several legislatures. Justice Thomas's Dobbs concurrence explicitly invited reconsideration of Griswold v. Connecticut, the 1965 ruling establishing constitutional protection for contraception access. The Right to Contraception Act, federal legislation explicitly protecting contraception access, has been introduced in multiple sessions; it has not yet been enacted but has produced useful position-clarifying votes. State-level action — codification of contraception access in state law, expansion of pharmacist-prescribed contraception, OTC access — provides the most active reform avenue.

In February 2024, the Alabama Supreme Court ruled that frozen embryos used in IVF treatment qualified as 'extrauterine children' under state law, exposing IVF clinics to wrongful-death liability for routine practices including embryo discard. IVF treatment in Alabama paused immediately. The ruling exposed a fault line that legal observers had warned about: 'fetal personhood' frameworks, advanced in service of abortion restrictions, also threaten IVF, which routinely involves creating, freezing, screening, and (sometimes) discarding embryos. The federal political response was rapid. The Right to IVF Act, federal statutory protection for IVF treatment regardless of state-level personhood frameworks, was introduced and has had Senate floor votes. Alabama itself enacted a temporary statutory shield. The longer-term question is whether state-level personhood frameworks continue to spread, what they mean for IVF, and whether the federal lever (statutory protection, possible action under HHS) can keep ahead of the state-level pressure.

Maternal mortality in the US is the worst among advanced economies and has been rising. The Black maternal mortality rate is roughly three times the white maternal mortality rate, a gap that has widened. The crisis intersects multiple structural failures: inadequate prenatal care access (especially in rural areas where labor-and-delivery units have closed at scale), Medicaid postpartum coverage that until recently expired at 60 days, mental-health support gaps, racial disparities in clinical care that produce worse outcomes for Black mothers regardless of socioeconomic status. The federal response — the Black Maternal Health Momnibus package — addresses these systematically. Most components remain in committee; one (twelve-month postpartum Medicaid extension) has been adopted by most states but not all. Rural maternal health requires a parallel push: federal support for L&D operations at low-volume rural hospitals, midwifery and birth-center expansion, telehealth-supported prenatal care that doesn't substitute for in-person delivery.

Patients in restrictive states who travel for abortion or other reproductive care face several vectors of legal and digital exposure. Period-tracking apps, location data from phones, internet search histories, and credit card records can all become evidence in state-level prosecutions for violating travel restrictions or abortion bans. Healthcare providers in destination states face uncertain exposure to subpoenas, extradition requests, and license challenges from origin states. State-level shield laws — enacted in California, New York, Massachusetts, Connecticut, Illinois, Colorado, and others — provide statutory protection for providers and patients against out-of-state legal action. Federal action on digital privacy specifically tied to reproductive care has advanced incrementally (HIPAA Privacy Rule modifications by HHS, FTC enforcement against data brokers selling location data) but remains far from comprehensive. The political and legal frontier is being defined in real time, with active litigation over the constitutionality of state-level travel restrictions, the reach of state subpoenas across state lines, and the application of HIPAA to reproductive-care data.